过去一年，核酸药物市场热闹非凡，在罕见病、遗传病、乙肝、肥胖、肿瘤等领域都展现出治疗潜力，吸引众多药企布局。据统计，2024年该领域潜在交易总金额达到208亿美元。 日前，ASO龙头Ionis ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...

Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis Pharmaceuticals for the treatment of polycythemia vera (PV). The licence ...

(Carlsbad, CA,U.S.; CEO, Brett P. Monia, Ph.D.; “Ionis”) for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Sapablursen is currently being evaluated ...

Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired exclusive global rights from IONS to develop and market sapablursen, an ...

Ionis will receive $280M upfront from Ono ... Sapablursen, an investigational RNA therapy for polycythemia vera, is in a fully enrolled Phase 2 trial. How to Spot the Market Bottom: Matt Maley ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license a ...

Ionis Pharmaceuticals licensed out its investigational antisense oligonucleotide sapablursen to Ono Pharmaceutical on Tuesday, giving the Japanese firm exclusive global rights to develop and ...

The Ionis-Ono deal is “positive for both sides,” Minter said. It gives Ionis cash to continue pursuing the development of wholly owned drugs, while giving Ono an experimental medicine that’s poised to ...